Positive results reported for fight against VHF

Peregrine Pharmaceuticals, Inc., has announced that its researchers have presented positive data on progress as part of its federally funded preclinical viral hemorrhagic fever program.

The data confirms that its phosphatidylserine-targeting antibodies bind to VHF viruses, virally infecting cells and increasing survival in a model of a lethal VHF infection.

Peregrine's interim data stems from multi-year program to assess the company's phosphatidylserine-targeting antibodies as broad-spectrum agents for the treatment of viral hemorrhagic fevers, which carry a potential of biodefense threats.

The study by Peregrine evaluated the activity of the antibodies against representatives of major VHF virus families, confirming that broad spectrum phosphatidylserine-targeting antibodies bind to VHF viral particles. The study also demonstrated that Peregrine's antibodies bind to mammalian cells infected with hemorrhagic fever viruses.

The antibodies were also found through pharmacokinetic and dosing studies to be sustainable in the blood at therapeutically relevant concentrations.

Additionally, antiviral efficacy studies of the antibodies show that a single dose of Peregrine's antibodies increased the survival rate of hamsters infected with lethal doses of viruses from two different VHF virus families.

More efficacy studies, including repeat dose and combination therapy studies, are now underway based on the positive findings.

"These positive initial efficacy data after administration of only a single dose is an early confirmation of the potential of our anti-PS antibodies as broad-spectrum therapeutics for VHF," Steven W. King, president and CEO of Peregrine, said. "They also reflect the excellent progress being achieved by our multi-institutional project team. This first public presentation of data from our ongoing federally funded program is also consistent with our extensive preclinical and clinical experience showing the broad-spectrum antiviral potential of our PS-targeting technology platform and we look forward to sharing more results from the studies as further progress is made."